Search - tctmd.com

Displaying 601 - 620 of 621

Sort: Relevancy | Date

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

News Daily News

Broader, Primary Prevention Role for High-Sensitivity Troponin Tests Suggested by ARIC Analysis

Shelley Wood

June 10, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News EAS 2016

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

Yael L. Maxwell

May 31, 2016

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

Advertisement

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Broader, Primary Prevention Role for High-Sensitivity Troponin Tests Suggested by ARIC Analysis

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content